WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

REVIEW STUDY ON COMPARISION OF SAFETY AND EFFICACY OF EDARAVONE A NEUROPROTECTIVE DRUG IN INDIAN POPULATION STROKE PATIENTS

Shaik Tanisha Bibi*, B. Harsshene, Sreenu Thalla, N. Prathibha and Padmalatha Kantamaneni

ABSTRACT

Edaravone a free radical scavenger is the only neuroprotective agent effective for both Amyloid lateral sclerosis and Acute ischemic stroke treatment. Free radicals play a crucial role in brain ischemic injury by exacerbating membrane damage through peroxidation of unsaturated fatty acids of cell membrane leading to neuronal death and brain edema. Hence use of a free radical scavenger is very much essential in such conditions. Oxidative stress is a viable target in stroke therapy which can be reduced by the use of edaravone. The studies we mentioned aims at the safety and efficacy of Edaravone in a group of Indian population of acute ischemic stroke patients. Study 1 was an open label prospective study which was conducted in the Department of Neurology, CSM Medical University, Lucknow, a tertiary health care centre in North India. The study was carried out between January and July 2008. Study 2 was a prospective open labeled, randomized controlled study conducted in the Department of Neurology, Chatrapathi Shahuji Medical University, Luck now, and a tertiary health care centre in North India. The study was conducted between May 2009 and May 2010. All the patients received 30mg of Edaravone dissolved in 100ml of normal saline infusion over 60 minutes twice for 14 days. The outcome assessment was done by using the Modified Rankin Scale (MRS) and the Barthel Index (BI). MRS score ≤ 2 at 90 days was considered to be favorable outcome. In study 1 and the mean MRS score decreased at day 7 to day 14 to day 30 to day 90(p<0.05). The mean Barthes index increased at day 7(p<0.05) from baseline, to day 14 to day 30 to day 90(p<0.05). In study 2 the mean MRS decreased from baseline at 90 days in Edaravone group. The difference in mean MRS was not significant between two groups (P=0.0590). The mean BI increased from 41.20±32.70 at baseline to 82.40±18.32 at day 90 in the edaravone group as compared with 68.20±21.30 at 90 days in the placebo group. Both the studies concluded that there was safe and effective outcomes of Evaradone among the stroke patients and did not experience any major side effects.

Keywords: Edaravone, neuroprotective drug, free radical scavenger, both ALS and AIS treatment.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More